Global Brucellosis Market Segmentation, By Treatment (Medication and Others), Transmission (Raw Dairy Products, Inhaling Contaminated Air, Infected Blood & Body Fluids, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
Brucellosis Market Analysis
The brucellosis market is expanding due to the rising incidence of brucellosis, especially in regions reliant on livestock. Recent developments include advancements in diagnostic technologies, such as PCR tests and serological assays, enabling early and accurate detection. Vaccination programs for brucellosis livestock have also seen improvements, with new vaccines offering better efficacy. Market analysis indicates growing demand for diagnostic kits, vaccines, and treatments, particularly in Asia-Pacific, Latin America, and Africa, where the disease burden is higher. Government initiatives, international collaborations, and increasing funding for R&D are helping to boost market growth. However, challenges such as underreporting, lack of awareness in rural regions, and the need for more effective treatments persist. Ongoing innovations and strategic partnerships are expected to further drive market expansion.
Brucellosis Market Size
The global brucellosis market size was valued at USD 276.43 million in 2023 and is projected to reach USD 393.11 million by 2031, with a CAGR of 4.50% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Brucellosis Market Trends
“Rising Prevalence of This Zoonotic Disease”
The brucellosis market is witnessing growth due to the rising prevalence of this zoonotic disease, particularly in livestock-dependent regions. brucellosis, caused by brucella bacteria, spreads through raw dairy products, contact with infected animals, and contaminated air. Innovations in diagnostics, such as PCR and ELISA tests, have improved early detection, while new, more effective livestock vaccines are being developed to prevent transmission. A key trend is the increasing focus on preventive measures, including vaccination campaigns and enhanced veterinary care in high-risk areas. The market is driven by growing awareness, improved healthcare infrastructure, and government-backed initiatives, particularly in developing countries.
Report Scope and Brucellosis Market Segmentation
|
Attributes
|
Brucellosis Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Fresenius SE & Co. KGaA (Germany), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), HIKMA PHARMACEUTICALS PLC (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Bayer AG (Germany), Colorado Serum Company (U.S.), Indian Immunologicals Ltd. (India), HESTER BIOSCIENCES LIMITED (India), JOVAC (Jordan)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Brucellosis Market Definition
Brucellosis is a zoonotic infection caused by brucella bacteria, primarily transmitted to humans through direct contact with infected animals, consumption of unpasteurized dairy products, or inhalation of contaminated particles. It causes flu-like symptoms, including fever, joint pain, and fatigue, and can lead to chronic health issues if untreated. It primarily affects livestock, making it a significant public health concern.
Brucellosis Market Dynamics
Drivers
- Rising Incidence in Vaccination Programs
The development and implementation of effective vaccines for livestock are crucial market drivers for brucellosis prevention efforts. Vaccination plays a vital role in controlling the spread of the disease, as it significantly reduces the incidence of brucellosis in animal populations. By immunizing livestock, the risk of transmission to humans through contaminated milk or direct contact is greatly diminished. Enhanced vaccine formulations, offering improved efficacy and safety profiles, are being developed and adopted globally. This proactive approach safeguards public health and protects livestock productivity, ensuring food security and economic stability for farmers, thereby increasing the overall demand for vaccines in the market.
- Increased International Trade and Travel
The increased international trade of livestock and animal products significantly heightens the risk of brucellosis transmission across borders, acting as a critical market driver for enhanced control measures. As countries engage in global commerce, the movement of infected animals and contaminated products can lead to outbreaks in previously unaffected regions. This scenario necessitates the implementation of robust brucellosis control strategies, including stringent testing, monitoring, and vaccination programs. Governments and health organizations are compelled to invest in effective diagnostics and treatment solutions to mitigate the risks associated with this trade. Consequently, the demand for advanced brucellosis management tools and practices is expected to rise, promoting market growth.
Opportunities
- Integration of Telemedicine for Veterinary Care
The integration of telemedicine for veterinary care and remote diagnostic solutions represents a significant market opportunity in combating brucellosis, particularly in rural areas. By utilizing telemedicine, veterinarians can provide timely consultations, enabling farmers to address health concerns in livestock promptly without the need for extensive travel. Remote diagnostic technologies allow for quicker testing and analysis, facilitating early detection of brucellosis cases. This enhanced accessibility improves response times and empowers farmers with the necessary tools and knowledge to manage their herds effectively. As rural areas often face limitations in veterinary services, this integration can drive demand for innovative solutions, promoting overall market growth.
- Increasing Emphasis on Biosecurity
The increased emphasis on biosecurity in livestock farming presents a compelling market opportunity for brucellosis control products and services. As awareness of zoonotic diseases grows, farmers are prioritizing biosecurity measures to protect their herds from infections such as brucellosis. Implementing strict biosecurity protocols, such as controlling access to livestock, maintaining clean environments, and conducting regular health checks can significantly reduce the risk of disease transmission. This shift in focus creates a heightened demand for vaccines, diagnostic tools, and educational resources that support biosecurity efforts. Consequently, companies providing innovative solutions in biosecurity are well-positioned to capture a larger share of the brucellosis market, driving growth and improving overall herd health.
Restraints/Challenges
- Underreporting and Misdiagnosis
Many cases of brucellosis go unreported or misdiagnosed due to the disease's non-specific symptoms, such as fever, fatigue, and joint pain, which can mimic other common illnesses. This lack of clear differentiation results in an underestimation of its true prevalence, complicating public health efforts and hindering effective control measures. The limited awareness among healthcare professionals, especially in rural and resource-limited settings, further exacerbates this issue. As a consequence, without accurate data on infection rates, it becomes challenging to allocate resources effectively, implement targeted interventions, and develop strategies to educate communities, ultimately impeding progress in managing and controlling brucellosis outbreaks.
- High Cost of Effective Treatments and Diagnostics
The cost of effective treatments and diagnostics for brucellosis can be prohibitively high, presenting a significant restraint on market growth. Many healthcare systems, particularly in developing countries, struggle with limited budgets and resources, making it difficult to allocate funds for essential interventions. Farmers, especially those in low-income regions, may find it challenging to invest in costly diagnostic tests and treatments for their livestock. This financial burden can lead to delayed or inadequate responses to brucellosis outbreaks, hindering effective disease management. Consequently, the high costs associated with these interventions restrict access to vital resources, ultimately affecting public health outcomes and exacerbating the spread of the disease.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Brucellosis Market Scope
The market is segmented on the basis of treatment, transmission, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Others
Transmission
- Raw Dairy Products
- Inhaling Contaminated Air
- Infected Blood & Body Fluids
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Brucellosis Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, treatment, transmission, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America leads the brucellosis market, attributed to its access to advanced technologies and significant investment in research and development. The region's high healthcare expenditure fosters innovation in diagnostics and treatments, enhancing disease management capabilities. This strong focus on technological advancement and R&D positions North America as a key player in the global brucellosis market.
Europe has experienced positive growth in the global brucellosis market, driven by an increase in animal husbandry and poultry farming. The region's robust agricultural sector, coupled with the presence of numerous generic manufacturers, has further supported this growth. This combination of factors has positioned Europe as a significant contributor to the overall expansion of the brucellosis market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Brucellosis Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Brucellosis Market Leaders Operating in the Market Are:
- Fresenius SE & Co. KGaA (Germany)
- Pfizer Inc (U.S.)
- Viatris Inc. (U.S.)
- Novartis AG (Switzerland)
- HIKMA PHARMACEUTICALS PLC (U.K.)
- Aurobindo Pharma (India)
- AbbVie Inc. (U.S.)
- Bayer AG (Germany)
- Colorado Serum Company (U.S.)
- Indian Immunologicals Ltd. (India)
- HESTER BIOSCIENCES LIMITED (India)
- JOVAC (Jordan)
Latest Developments in Brucellosis Market
- In March 2024, Boehringer Ingelheim, a prominent player in the animal health industry, partnered with Square Pharmaceuticals to introduce Aftovaxpur in Bangladesh. This innovative vaccine is designed to combat foot-and-mouth disease (FMD) in ruminants, such as cattle and sheep. The launch aims to improve livestock health and bolster the agricultural sector in the region
- In April 2023, scientists at Cornell University's College of Veterinary Medicine (CVM) developed a novel diagnostic test for identifying Brucella canis. This innovative test enables early diagnosis of the zoonotic disease, which can be transmitted to humans through contact with infected dogs. As a result, this advancement is expected to promote increased vaccination efforts over time
- In April 2022, Ceva Santé Animale and Mitsui & Co., Ltd. formed a joint venture to expand veterinary laboratory capabilities in Japan. This collaboration aims to tackle the challenges related to animal diseases and food safety within the country. As a result, this initiative is anticipated to significantly contribute to market growth by enhancing disease management and ensuring safer food production practices
- In September 2020, Hester Biosciences announced an agreement to acquire indigenous technology from ICAR-IVRI (Indian Council of Agricultural Research - Indian Veterinary Research Institute) for developing the Brucella Abortus S19 Delta Per vaccine. This strategic move enabled the company to expand its product portfolio and enhance its offerings in the veterinary vaccine market. Consequently, it is expected to boost revenue generation and strengthen Hester Biosciences' position in the industry
SKU-